Tags : Blockbuster

Novartis Highlights its Blockbuster Portfolio at R&D Day 2019

Shots: Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or first-in-indication therapies. Novartis emphasizes its focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms Novartis presents its emerging assets including Iscalimab […]Read More